Cyber risk and business interruption repeat as top two risks on Aon’s biennial Global Risk Management Survey As conflicts disrupt an interconnected world, business leaders rank supply chain at highest risk level in 14 years Despite headlines, leaders do not rank climate and AI among highest risks

DUBLIN, Nov. 7, 2023 /PRNewswire/ — Aon plc (NYSE: AON), a leading global professional services firm, today announced the results of its 2023 Global Risk Management Survey, which gathered input from almost 3,000 risk managers, C-suite leaders and other executives from 61 countries and territories to identify their most-pressing business challenges.

"The world is more volatile, reflecting a series of profound transitions across trade, technology, weather and workforce issues that have awoken business leaders to the increasingly interconnected nature of risk and people challenges," said Aon CEO Greg Case. "Through the use of advanced analytics and more integrated Risk Capital and Human Capital capabilities, we’re helping clients quantify, manage and match capital to the risks they recognize today as we innovate on their behalf to serve their future needs."

Now in its 17th year, the 2023 edition of Aon’s biennial survey found that human capital issues are no longer simply a "people problem," but a key business risk that is fueled by rising health care costs, the competition for talent, workforce shortages, and a lack of retirement preparedness. In 2023, "attracting and retaining top talent" ranked fourth globally, after not breaking the top 10 in 2021, demonstrating a shift in how risk managers are viewing human capital today. Still, only 11 percent of survey respondents indicated they have quantified their people risks, illustrating a significant gap between risk awareness and risk preparedness.

"We are at a pivotal moment in time, when business leaders are recognizing the true cost of human capital challenges and the reality that people risk intensifies all other top business risks," said Lambros Lambrou, CEO of Human Capital at Aon. "Shortfalls in talent, workforce or critical specialized skills can hamper innovation and competitiveness and increase exposure to cyberattacks, regulatory breaches, supply chain issues, business interruption and reputational damage."

Despite warnings and headlines, climate (#17) and artificial intelligence (AI) (#49) are notably missing from the global top 10 ranking, suggesting a lack of awareness about the potential impact of these issues on the corporate risk profile. More immediate climate driven risks include property damage, impact of severe weather, natural catastrophes, and the consequences for business of climate-related regulatory changes and compliance obligations.

"What is more confounding are the risks that are noticeably unaccounted for in leaders’ assessments of the challenges they must address, notably climate risk," said Andy Marcell, CEO of Risk Capital and CEO of Reinsurance Solutions at Aon. "Climate is not an emerging risk, but an urgent one, with increasingly monumental implications for businesses of all sizes. What leaders need now are insights from advanced analytics and modeling alongside innovative parametric solutions that will help them make better decisions today and protect them in the future."

Additionally, AI represents one of the most pressing concerns amid technological advancement, as it will transform the enterprise risk landscape for all industries, introducing new risks for many companies and changing the severity and velocity of change of many existing risks. For instance, far-reaching AI programs could increase cybersecurity exposure, engender legal issues and amplify human capital risks such as scarcity of in-demand skills sets. Risk managers who understand the liabilities and insurance implications of AI across their digital value chain add value to their enterprise AI strategy.

As conflicts, geopolitical change, and macroeconomic conditions continue to have broad-reaching impacts, business leaders also ranked the risk of supply chain and distribution failure at its highest level in 14 years (#6). According to the latest survey, less than 40 percent of organizations have conducted supplier resiliency assessments and less than 20 percent have diversified their supplier base to mitigate supply chain or distribution failure risk. Insufficient mitigation efforts, therefore, appear to be correlated closely with a rise in perceptions of supply chain/distribution risk exposure. 

Cyber attacks and data breaches remain the top risk in this year’s survey, both globally and in North America, and they have also climbed to the top spot in Europe and Asia Pacific. Cyber shows the highest level of risk readiness, and consistent with that, it has one of the lowest reported losses of income and one of the highest percentages of risk mitigation actions across all top ten risks. Business interruption remains the number two risk since Aon’s 2021 survey, reflecting the reality that business interruption events are increasing and can affect multiple industries and companies simultaneously.

Overall, the top ten global risks according to the 2023 Global Risk Management Survey are:

Cyber Attacks/Data Breach Business Interruption Economic Slowdown/Slow Recovery Failure to Attract or Retain Top Talent Regulatory/Legislative Changes Supply Chain or Distribution Failure Commodity Price Risk/Scarcity of Materials Damage to Reputation/Brand Failure to Innovate/Meet Customer Needs Increasing Competition

Notably only two of the top five current risks are insurable and half of the overall top ten is presently uninsurable.

Conducted every two years since 2007, Aon’s Global Risk Management Survey provides data and insights to enable better decision making around risk in an increasingly volatile and complex business environment.

The full Global Risk Management Survey report is available here.

About Aon
Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Our colleagues provide our clients in over 120 countries and sovereignties with advice and solutions that give them the clarity and confidence to make better decisions to protect and grow their business. 

Follow Aon on LinkedIn, Twitter, Facebook and Instagram. Stay up-to-date by visiting the Aon Newsroom and sign up for News Alerts here.

Media Contact
[email protected] 
Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114
International: +1 312 381 3024

Source : Failure to Attract and Retain Talent Reaches Highest Ever Ranking in Aon Survey, Elevating Human Capital as a Key Business Risk

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

DUBLIN, Nov. 7, 2023 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2024 on Tuesday, November 21, 2023. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company’s second quarter of fiscal year 2024, which ended on Friday, October 27, 2023.

Medtronic will host a video webcast at 7:00 a.m. CST on Tuesday, November 21, 2023, to discuss results for its second quarter of fiscal year 2024. The webcast can be accessed at https://investorrelations.medtronic.com.

Within 24 hours of the broadcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investorrelations.medtronic.com.

Looking ahead, Medtronic plans to report its fiscal year 2024 third and fourth quarter results on Tuesday, February 20, 2024, and Thursday, May 23, 2024, respectively. For these events, confirmation and additional details will be provided closer to the specific event.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Erika Winkels

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-8478

+1-763-505-4626

Source : Medtronic to announce financial results for its second quarter of fiscal year 2024

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

NFL LEGEND MOVES SOUTH TO TEXAS.

OUT-OF-STATE INTERESTS VENTURE NOW DEVELOPING LARGE SCALE MULTIFACETED EQUINE COMPLEX ON 800-ACRE FACILITY.

DALLAS, Nov. 7, 2023 /PRNewswire/ — The Icon Global Group has announced the completed sale of the Bradshaw Ranch owned by NFL Quarterback Legend and Host of Fox TV NFL Sunday, Terry Bradshaw.  Bradshaw recently closed the sale of his long-time ranch and home near Thackerville, Oklahoma, handing off more than twenty years of ownership.  The enormous homestead on the sprawling almost 800-acre property was also the primary filming location for E Entertainment Television’s, "The Bradshaw Bunch".  The extensive property was also an intensive grazing and working cattle operation as well as being an internationally renowned breeder of world champion halter class quarter horses. It was listed on the market for $22.5 million dollars.

The property has been re-branded as Red River Equine.  The ranch is being re-developed and marketed as a large-scale premiere breeding, training, and sales preparation facility catering to several different aspects of the American Quarter Horse industry. The facility will stand a variety of specialty proven stallions for breeding, provide embryo transfer as well as other niche management and breeding practices focused on augmenting various alternative breeder, trainer, and competitor needs in the rapidly growing sector of the horse industry.

The new ownership is a joint venture between two formerly out-of-state identities, Billy, and Suzzone Franks of Texas, together with Chad and Tiffeny Beus who have relocated from Utah to lead the venture development.  Beus stated, "We chose this location and facility because of its very central geographical location to all points within the region, especially central to Texas and Oklahoma. This is important to our clientele and to the expansion requirements of our business. The large size of the ranch with its already established infrastructure and first-class facilities of the long-standing Bradshaw operation was a perfect platform from which to not only launch our operations but importantly to build upon, improve, and diversify he said.

Terry Bradshaw said, "The decision-making process to finally selling has been a long and winding road. Along the way, we have been presented with and considered many great offers, opportunities, and proposals. However, between my own schedule, the TV series, my family’s changing needs, our horse and cattle business, as well as many other commitments, neither timing nor opportunity was ever on our side or completely aligned. Plus, and frankly, I loved this ranch so much, having built it from the ground up, so I was very tied to it. Tammy and I really didn’t want to make the final break until we found our perfect sunset opportunity to do what we enjoy on a smaller scale and in a place, we absolutely love, and we found that.   Working with Bernie Uechtritz and his Team over at Icon Global has really been phenomenal. Tammy and I appreciate Bernie’s long-time professionalism, patience, personality, and counsel.  I sincerely recommend Icon Global to anyone within the equestrian, ranching, and land business needs, whether simplistic or especially complex like our deal."

Icon Global founder Bernard Uechtritz added, "This important sale was the culmination and alignment of the efforts of many people, teams, and factors over time, and far too many to mention everyone involved. However, I do want to especially recognize and thank my good friends and professional associates starting with Bill Fandel in Telluride, Colorado, as well as Jeff Boswell and Brian Pickens in Dallas and Houston, all of whom were integral to the team at Icon’s success formula in getting this deal beginning to end, across the line. In addition, Jay Winborne president of the NCHA, and his own marketing folks also assisted greatly in Icon’s efforts to cast a wide marketing net across the NCHA spectrum of the horse industry, which in fact very much helped our cause.  Michael Ferguson and his team at Capital Farm Credit in Bryan were masterful in leading the critical financing aspects of the sale which closed in record time despite what Mother Nature and Murphy’s law had thrown at us along the way. We were able to announce the call for offers marketing in April and then complete our closed sale process in just a couple of months" – END

Bradshaw Ranch – select photos
About Icon Global

www.icon.global

Source : ICONIC TERRY BRADSHAW OKLAHOMA RANCH SOLD

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Signs a multi-year agreement for intelligent and intuitive digital solutions

SINGAPORE and MUMBAI, India, Nov. 7, 2023 /PRNewswire/ — Tata Communications, a global digital ecosystem enabler and Singapore Airlines Limited (SIA), the national carrier of Singapore, announced a multi-year agreement to transform the airlines communications and collaboration tools to enhance employee productivity and boost user experience.

SIA and Tata Communications have a successful, long-standing association that has been strengthened over several years. This new transformative initiative delivered on Tata Communications GlobalRapide platform enables SIA users to be connected and collaborative anytime and anywhere globally.

"We take great pride in our long-standing relationship with Singapore Airlines. As a global CommTech player, we are privileged to be chosen as their partner in progress as they emerge stronger than ever and strive to create new benchmarks in customer experiences," said Amitabh Sarkar, Vice President & Head of Asia Pacific and Japan – Enterprise, Tata Communications.

Tata Communications has been working with SIA for the last five years and in addition to the above solutions, Tata Communications IZOTM SDWAN also enables SIA with intelligent customer call routing to their global customer service centres, ensuring a seamless customer experience.

Additionally, SIA pilot and cabin crew collaboration platforms are also powered by Tata Communications MOVE enabling global and always connected experience to the crew. MOVE global intelligent cellular connectivity facilitates a swift and secure exchange of critical flight and passenger data on pilots and crew tablets, leading to expedited flight turn-round and enhanced on-time performance while achieving significant cost savings compared to traditional data roaming solution.                                                                            

About Tata Communications

A part of the Tata Group, Tata Communications (NSE: TATACOMM; BSE: 500483) is a global digital ecosystem enabler powering today’s fast-growing digital economy in more than 190 countries and territories. Leading with trust, it enables digital transformation of enterprises globally with collaboration and connected solutions, core and next gen connectivity, cloud hosting and security solutions and media services. 300 of the Fortune 500 companies are its customers and the company connects businesses to 80% of the world’s cloud giants. For more information, please visit www.tatacommunications.com        

Twitter

Facebook

LinkedIn

Instagram

YouTube

Forward-looking and cautionary statements

Certain words and statements in this release concerning Tata Communications and its prospects, and other statements, including those relating to Tata Communications’ expected financial position, business strategy, the future development of Tata Communications’ operations, and the general economy in India, are forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors, including financial, regulatory and environmental, as well as those relating to industry growth and trend projections, which may cause actual results, performance or achievements of Tata Communications, or industry results, to differ materially from those expressed or implied by such forward-looking statements. The important factors that could cause actual results, performance or achievements to differ materially from such forward-looking statements include, among others, failure to increase the volume of traffic on Tata Communications’ network; failure to develop new products and services that meet customer demands and generate acceptable margins; failure to successfully complete commercial testing of new technology and information systems to support new products and services, including voice transmission services; failure to stabilize or reduce the rate of price compression on certain of the company’s communications services; failure to integrate strategic acquisitions and changes in government policies or regulations of India and, in particular, changes relating to the administration of Tata Communications’ industry; and, in general, the economic, business and credit conditions in India. Additional factors that could cause actual results, performance or achievements to differ materially from such forward-looking statements, many of which are not in Tata Communications’ control, include, but are not limited to, those risk factors discussed in Tata Communications Limited’s Annual Reports. 

The Annual Reports of Tata Communications Limited are available at www.tatacommunications.com. Tata Communications is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements.

© 2023 Tata Communications Ltd. All rights reserved.

TATA COMMUNICATIONS and TATA are trademarks or registered trademarks of Tata Sons Private Limited in India and certain countries.

Source : Singapore Airlines partners with Tata Communications to enhance customer experience for their discerning customers

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Nov. 7, 2023 /PRNewswire/ — Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus oxaliplatin (XELOX) compared to placebo plus XELOX in for first-line treatment of unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC). The trial achieved its primary endpoint by demonstrating a statistically significant overall survival (OS) improvement. The Independent Data Monitoring Committee (IDMC) recommended the early submission of a supplemental new drug application (sNDA) for cadonilimab in this indication based on the interim analysis.

The interim analysis showed that cadonilimab plus chemotherapy significantly improved OS in the all-comer patients irrespective of PD-L1 status, compared to placebo plus chemotherapy, meeting the pre-defined efficacy criteria. The safety profile remained consistent with previous results, with no new safety signals identified. These data will be presented in future international academic conferences/journals.

Interim Analysis Highlight:

Cadonilimab combined with chemotherapy significantly reduces the risk of death in all-comer patients, including whose with PD-L1 CPS≥5 and PD-L1 CPS<5. The hazard ratios (HRs) for OS in patients with different PD-L1 status were superior to other disclosed PD-1 plus chemotherapy combination treatment. The combination of cadonilimab and chemotherapy also demonstrated superior OS in patients with PD-L1 CPS<5 as well as PD-L1 negative, maintaining the excellent performance seen in the phase II study.

"We extend our sincere gratitude to all the investigators, participants, and patients who actively took part in the clinical trial," expressed Dr. Yu Xia, Founder, Chairman, President, and CEO of Akeso. " Thanks to your dedication and efforts, an estimated 500,000 gastric cancer patients in China may have access to a new bispecific IO drug combination therapy offering improved treatment efficiency and survival prospects. We will continue to adhere to the recommendations of IDMC, efficiently promote the study, and engage in proactive communication with China’s National Medical Products Administration (NMPA) regarding the marketing application of cadonilimab for this new indication. We eagerly anticipate the early approval of this innovative therapy for the benefit of patients."

ABOUT AK104-302

AK104-302 is a Phase III clinical trial evaluating the use of cadonilimab (which is the world’s first approved PD-1/CTLA-4 bi-specific antibody) in combination with XELOX as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). This randomized, double-blind, multi-center study aims to assess the efficacy of cadonilimab plus XELOX compared to placebo plus XELOX in the intent-to-treat (ITT) population.

The AK104-302 trial represents the first Phase III clinical study of a PD-1/CTLA-4 bispecific antibody combined with chemotherapy for first-line treatment of gastric cancer. Approximately 60% of patients in the ITT population had a PD-L1 CPS＜5, a proportion comparable to real-world scenarios.

About Cadonilimab

Cadonilimab is a first-in-class bispecific antibody that targets both PD-1 and CTLA-4 developed by Akeso. It is a symmetric tetravalent bispecific antibody with a crystallizable fragment (Fc)-null design. In addition to demonstrating biological activity similar to that of the combination of CTLA-4 and PD-1 antibodies, cadonilimab possesses higher binding avidity in a high-density PD-1 and CTLA-4 setting than in a low-density PD-1 setting, while a mono-specific anti-PD-1 antibody does not demonstrate this differential activity. With no binding to Fc receptors, cadonilimab shows minimal antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and interleukin-6 (IL-6)/IL-8 release. These features all likely contribute to significantly lower toxicities of cadonilimab observed in the clinic. Higher binding avidity of cadonilimab in a tumor-like setting and Fc-null design may lead to better drug retention in tumors and improve safety while achieving anti-tumor efficacy.

The China National Medical Products Administration has approved cadonilimab for recurrent or metastatic cervical cancer. Cadonilimab has been included and recommended in multiple clinical guidelines such as CSCO. Cadonilimab has been engaged in more than 60 ongoing clinical trials including investigator-initiated studies. Patient enrollment has been completed for the phase 3 study of cadonilimab for first-line treatment of advanced cervical cancer. A phase 3 study of cadonilimab as an adjuvant treatment for hepatocellular carcinoma is ongoing. Furthermore, a Phase 3 study comparing cadonilimab with chemotherapy to tislelizumab Injection with chemotherapy is underway for the first-line treatment of PD-L1 expression-negative non-small cell lung cancer.

About Akeso, Inc.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address significant medical needs globally. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.

Akeso is actively developing a diverse pipeline of over 30 innovative assets in areas such as cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, NDAs for 4 drugs and 6 indications accepted, and 13 ongoing Phase III studies. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug to the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

In June 2022, cadonilimab was approved by the NMPA and became the first commercialized bispecific IO drug globally. Another Akeso internally discovered and developed oncology product, penpulimab (a PD-1 antibody), was granted marketing approval in China in August 2021. In December 2022, Akeso entered into a collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of ivonescimab. In August, the NDA submission of ivonescimab was accepted by China’s NMPA and granted Priority Review. Akeso is listed on the Main Board of the Stock Exchange of Hong Kong Limited.

Contact Akeso Public Relations:
[email protected]

Contact Akeso Business Development:
[email protected]

For more information, please visit https://www.akesobio.com/en/ and follow us on X (formerly Twitter) @Akeso Inc., and Linkedin @Akeso Inc. 康方生物

Source : Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ — Recently, CPHI Worldwide 2023 was successfully held in Barcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab, and Trastuzumab, etc., which attracted many customers to stop by for negotiation.

Although Kexing Biopharm specially booked a large booth including independent conference rooms for this exhibition, the seats were still packed with customers who came in an endless stream, and the scene was extremely popular. Many overseas customers expressed great interest in several high-end drugs shown by Kexing Biopharm, and actively explored joint development of overseas business with the company.

Among the visitors at Kexing Biopharm’s booth, in addition to many "old friends", there were also many "new faces". Throughout the three-day exhibition, Kexing Biopharm’s overseas marketing team successfully connected with more than 200 esteemed clients, including leading international pharmaceutical companies. The participating team of Kexing Biopharm exchanged experiences and discussed with industry leaders, aiming to explore the future development of the industry.

Now, Kexing Biopharm is accelerating the establishment of a "high-quality biopharmaceuticals overseas platform" aiming to enhance the accessibility of bio-pharmaceutical products in more countries and regions to benefit more patients around the world. Currently, domestic drugs going to overseas markets has become a consensus among many Chinese pharmaceutical enterprises. As one of the first Chinese biopharmaceutical companies to go global, with over 20 years of experience in overseas commercialization, extensive marketing channels across over 40 countries, and a large professional service team, Kexing Biopharm has continuously proved its overseas commercialization strength with one milestone after another, and it is becoming an excellent partner for an increasing number of Chinese companies going overseas.

Source : Kexing Biopharm Attended CPHI Worldwide 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

CHANGZHOU, China, Nov. 7, 2023 /PRNewswire/ — Trina Solar has won the 2024 German Design Award for its Vertex S n-type dual-glass rooftop PV module series in the ‘Excellent Product Design’ category.

The German Design Award, founded by the German Design Council in 1953, is one of the world’s most prestigious design awards. Only works that have passed the review or recommendation of the German Design Committee can be nominated, and most of the nominated works are international design award-winning designs, also known as "winners among winners".

The recognition of the Vertex S+ modules’ design and aesthetic value by the German Design Awards follows the success of Trina Solar’s Vertex S module, which won the Red Dot Design Award, the international industrial design award known as the "Oscar" of the design world, last year.

Winning the German Design Award is not only confirmation of the creative design and performance of our module, but recognition of the entire concept of our Black Aesthetics range, which Vertex S+ is part of.

Trina Solar presents the perfect Black Aesthetics in every detail to a high standard. High uniformity between all cells, between cells and frames, and between modules ensures the integrity in building exterior design. The Black Aesthetics modules create more visual quality for users on their rooftops and promote the aesthetic experience of solar energy into thousands of homes worldwide.

Trina Solar launched the Vertex S+ dual-glass module series for rooftops in February, setting off a new round of PV aesthetics innovation in the global middle- and high-end residential market. Based on 210mm rectangular silicon wafer (210R) cell technology, this series of modules is combined with n-type i-TOPCon advanced technology, providing highest power, efficiency, and guaranteed lifetime power output. Its triple-cut cells have been designed for electrical compatibility with 99% of mainstream inverters, thus seamlessly integrating with existing system components. The 1.6+1.6mm lightweight dual-glass structure ensures ultra-high reliability and safety of the module, while maintaining the same low weight as comparable standard backsheet products.

Inheriting Trina Solar’s exclusive aesthetic black design, the NEG9RC.27 Clear Black module is the Vertex S+ series’ flagship product. It comes with black cells and a black frame. It incorporates bifacial cell technology with transparent encapsulation for additional power gain from the back side of the module, making it a universal premium solution for any type of residential and commercial rooftops. Additionally, it is perfect for specific application settings such as carports, public spaces, and agricultural projects.

On the other hand, the monofacial NEG9R.28 Vertex S+ module comes with a white encapsulant for top rated power output of up to 450Wp, thus maximizing performance on limited rooftop spaces.

The innovative Vertex S+ product series brings users a richer range of choices to customise and add more aesthetic possibilities to their roofs.

Source : Trina Solar wins prestigious international design award for Vertex S+

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network